

SUPPLEMENTARY MATERIAL

List of clinical questions

The Committee suggested the following clinical questions as key components, reviewed the latest data, and provided rationale and recommendations.

1. What is the updated knowledge on chronic hepatitis B (CHB) epidemiology and natural history?
2. What methods are recommended for hepatitis B prevention?
3. What preventive measures are needed to manage liver disease in patients with CHB?
4. What tests are needed for diagnosis and initial evaluation of CHB?
5. What are the ultimate goal and clinical endpoints of CHB treatment?
6. What are the updated criteria for treatment of CHB?
7. How do we follow up patients with CHB who are not indicated for treatment?
8. What is the best treatment strategy for CHB?
9. What are the newly approved drugs for CHB and what are their selection criteria?
10. What are the predictors of treatment response for CHB?
11. What should be monitored during antiviral therapy?
12. What are the appropriate cessation criteria of antiviral therapy?
13. How do we monitor after cessation of antiviral therapy?
14. What are the best strategies for managing antiviral-resistant CHB?
15. How do we deal with partial virological response during antiviral therapy?
16. What is the indication for treatment of CHB in patients with hepatocellular carcinoma (HCC)?
17. What are the considerations for choosing antiviral drugs in patients with renal impairment or metabolic bone disease?
18. Is antiviral treatment needed in acute hepatitis B patients?
19. How can we prevent reactivation of hepatitis B during immunosuppression and chemotherapy?
20. How can we prevent recurrence of hepatitis B after liver transplantation?
21. How can we prevent hepatitis B reactivation in other types of transplant patients?
22. How do we treat hepatitis B in patients with hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus (HIV) co-infection?
23. How do we treat CHB in pregnant women or women preparing for pregnancy?
24. How can we prevent mother-to-child transmission (MTCT) in pregnant women with CHB?
25. What is the updated knowledge of CHB treatment in children and adolescents?